Nikhil Vojjala, MD
@nikhil_vojjala
Followers
650
Following
1K
Media
27
Statuses
501
Internal Medicine @TrinityHealthMI | GLUE Scholar @WayneState | Alum @PGIChd @OMC | Hem-Onc fellowship applicant 2025-26 | Interest: Malignant Heme
Michigan, USA
Joined May 2022
RT @nmdp_org: 🚨 Transplant teams—need to quickly & clearly reference the 2025 Donor Selection Guidelines?. This new summary highlights:.• E….
0
6
0
RT @RahulBanerjeeMD: 1/ Our call to action is out in @BloodAdvances!. Title speaks for itself. Given concerningly high infection risk with….
0
37
0
RT @VincentRK: A historic day for myeloma!! .After 5 decades of research. European Commission / EMA approves Daratumumab as the first eve….
globenewswire.com
Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of...
0
51
0
RT @ZanwarSaurabh: A one stop shop for the current risk stratification schema in plasma cell disorders!. As always, thank you for being so….
0
20
0
RT @Abdallah81MD: Expanding Access to CAR T-Cell Therapy.How @KUcancercenter researchers helped make CAR T-cell therapy more accessible by….
0
13
0
RT @RitasmanB: 👉Facts on Majeed syndrome.👉Early onset CRMO .👉Treatment is by IL1 blockade.#ACR2204 #ACRAmbassador
0
9
0
RT @vsanchorawala: The Phase III CARES trial of #anselamimab in #ALAmyloidosis did not meet its primary endpoint, but showed clinically mea….
astrazeneca.com
0
12
0
RT @MaryCushmanMD: How often do your MPN patients get joint arthroplasty? In this analysis of claims data:.♥️ MPN patients had ⬆️ rates of….
0
3
0
RT @CIBMTR: Just Published in @ASTCT_Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.….
0
19
0
RT @Transplant_Doc: Primary impact of clonal hematopoiesis on the outcomes of BCMA CAR-T in MM: prolonged transfusion-dependent cytopenia….
ashpublications.org
TO THE EDITOR:
0
12
0
Hot off the press ! Rare complication of renoduodenal fistula in a patient with metastatic lung cancer now in Journal of Brown Hospital Medicine ! Greatful to my mentor @ibrahimazaronc @BrownJHM @BrownUniversity @THO_WSU_IM
1
0
9
Late post ! Had a great time @isth 2025. Meeting mentors, having oral sessions ! Icing on the cake is receiving early career investigator award ! I owe to both my mentors @vijsinghmd @rushadpatell.
2
2
14
RT @NausheenAhmedMD: ICE-T: Where immune cell therapy meets bold ideas, real talk, and the people actually doing the work. Don’t just hear….
0
3
0
RT @VincentRK: What’s up with Beta 2 microglobulin (B2M) and myeloma?. Why is it the sole non-cytogenetic marker used in the new IMWG high….
0
55
0
RT @SurbhiSidanaMD: WOW. No more REMS for all approved CAR-Ts per new FDA announcement . Decreased requirements fo….
fda.gov
The REMS for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been eliminated because the FDA has determined that a REMS is no longer...
0
6
0
RT @NikhilMunshiMD: Major Regulatory Milestone in MM: In response to an application by I2TEAMM and @IMFmyeloma, the European Medicines Agen….
0
38
0
RT @Haematologica: The debate on thrombotic thrombocytopenic purpura continues with a new comment by Professor Bernhard Lämmle on the lette….
0
7
0
RT @medoncodoc: 🧵 Game-changer for older #HodgkinLymphoma patients (≥60 yrs)!. In the SWOG S1826 trial, Nivolumab-AVD outperformed Brentuxi….
0
32
0
Happy to share, I have received YIP award, SOHO 2025 for old yet unanswered question: Len vs Mel oncogenic potential ! Grateful to my mentors @vijsinghmd @Amyloid_Planet @GK_SJMO @KarmanosHemeOnc and @deevyaparekh for collaboration!
6
1
37